DREAMM-5 Study: BLENREP Combined with Nirogacestat Presented at ASCO 2022
Dr. Sagar Lonial Discusses DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patients
Abstract Title:
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.
What is the purpose of this trial?
Preclinical data demonstrate that nirogacestat, a gamma-secretase inhibitor, may increase cell-surface levels of a B-cell maturation antigen (BCMA) and reduce soluble BCMA levels, which could enhance anti-BCMA agent activity in multiple myeloma. In the DREAMM-5 Phase I/II platform trial BLENREP (belantamab mafodotin), a BCMA-targeting antibody-drug conjugate, is being evaluated in combination with nirogacestat to determine if the combination can result in similar efficacy and an improved ocular safety profile compared to the currently approved belamaf schedule (single agent dose 2.5 mg/kg Q3W) in patients with relapsed/refractory multiple myeloma (RRMM) which showed a 31% overall response rate (ORR) and 44.5% Grade 3/4 keratopathy (BLENREP US prescribing information).
In this video:
Dr. Sagar Lonial (Winship Cancer Institute, Emory University—Atlanta, GA) discusses the DREAMM-5 Study: BLENREP (belantamab mafodotin-blmf) combined with gamma-secretase inhibitor nirogacestat at ASCO 2022
Conclusion:
Encouraging clinical activity and a manageable safety profile is observed with low dose belamaf (0.95 mg/kg Q3W) + nirogacestat (100 mg twice daily, continuously) in patients with RRMM. This ongoing sub-study is actively recruiting patients and will continue to evaluate belamaf + nirogacestat efficacy and safety. Updated results will be reported at the congress.
Clinical trial information: NCT04126200
Sagar Lonial, MD, FACP
(Winship Cancer Institute, Emory University—Atlanta, GA, USA)
Dr. Lonial is Professor and Chair of the Department of Hematology and Medical Oncology at the Emory University School of Medicine. He is Chief Medical Officer of the Winship Cancer Institute at Emory University and internationally recognized as a leading authority in multiple myeloma treatment and research. A medical oncologist at the Winship Cancer Institute, Dr. Lonial treats patients with multiple myeloma and is a lead member of the bone marrow transplantation and clinical trials teams. He is board certified in hematology and medical oncology. Dr. Lonial is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and American Society for Blood and Marrow Transplantation. Dr. Lonial is Vice Chair of the Finance Committee of the International Myeloma Society, and Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group. He also serves as President and Chair of the Society of Hematologic Oncology.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
